Drug Profile
Research programme: inflammation and rheumatoid arthritis therapeutics - Piramal Healthcare
Alternative Names: IL6 - Piramal; P 979Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Nicholas Piramal India Limited
- Developer Piramal Enterprises
- Class Small molecules
- Mechanism of Action Interleukin 6 inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in India
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in India (PO)
- 31 Dec 2008 Preclinical trials in Inflammation in India (unspecified route)